# PharmacoKINEtics of TAMoxifen and Its Metabolites in Breast Cancer Patients: the Influence of a Dose Increase in Phenotypic Poor Metabolizers of CYP2D6 (KINETAM)

> **NCT01192308** · PHASE1 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 42 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Tamoxifen 40mg QD

## Key facts

- **NCT ID:** NCT01192308
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2011-05
- **Final completion:** 2012-05
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2020-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01192308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01192308, "PharmacoKINEtics of TAMoxifen and Its Metabolites in Breast Cancer Patients: the Influence of a Dose Increase in Phenotypic Poor Metabolizers of CYP2D6 (KINETAM)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01192308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*